The patho-physiological role of somatostatin receptor subtypes (sst) in neuro endocrine diseases has gained enhanced scientific interest in the past few years. The development of novel somatotropinrelease inhibiting factor analogs, both sst-specific and universal ligands, seem promising as a tool to further increase fundamental insights in sst function. Eventually, this research should result in novel medical therapeutic opportunities in patients suffering from neuro-endocrine diseases. In the present review, the functional role of sst in all types of pituitary adenomas, based on recent preclinical and clinical studies, is being discussed.
Introduction
Somatostatin, also known as somatotropin-release inhibiting factor (SRIF), is a cyclopeptide that has broad inhibitory effects on the secretion of hormones such as growth hormone, insulin and glucagon. These effects have formed the basis for the clinical use of SRIFanalogs in the treatment of acromegaly and endocrine tumors. The discovery of the five SRIF receptor subtypes (sst) in the 1990s further enhanced the understanding of the biological roles of SRIF and SRIF analogs, and paved the way for new therapeutic opportunities. In this review, recent preclinical and clinical advances in ssttargeted treatment of human pituitary adenomas are discussed.
GH-secreting pituitary adenomas
Acromegaly is predominantly caused by a growth hormone (GH) secreting pituitary adenoma, resulting in high circulating GH and insulin-like growth factor I (IGF-I) hormone concentrations. Over the years, a triad of therapeutical options has been formed: surgery, irradiation and medical treatment (1). These treatment modules had the aim of inducing tumor shrinkage and normalizing GH and IGF-I levels, thereby reducing the risk of long-term complications including the development of malignant neoplasms, cardio-and cerebrovascular disease, respiratory and metabolic dysfunction (2). The clinical introduction of the longacting SRIF analogs in the early 1980s added a new dimension to the treatment of acromegaly (3) (4) (5) . The short half-life of SRIF and the subsequent need for i.v. administration however, as well as the post-infusion hypersecretion of GH, insulin and glucagon, has rendered the native peptide impractical for therapeutic use (6) . The short stable synthetic octapeptide SRIF analogs, octreotide (OCT) and lanreotide, appeared not to have these disadvantages and were administered in acromegalic patients to assess their role as a novel treatment option in acromegaly. Indeed, after the first reports that demonstrated the long-acting inhibitory effect of OCT on plasma GH levels, as well as a rapid amelioration of the clinical signs and symptoms, 20 years of endocrine practice and science has turned OCT and lanreotide into the widely accepted first medical treatment option for acromegaly (7) .
The current clinically available octapeptide SRIF analogs have been consistently shown to be able to reduce hormonal hypersecretion and to normalize IGF-I levels in a significant proportion of treated patients. Recently, Freda, summarizing the literature data on this topic (8) , showed the achievement of safe GH levels in 56% of patients treated with sandostatin-LAR (OCT incorporated into microspheres of a biodegradable polymer that results in therapeutical blood concentrations of the peptide for 24-42 days) and in 49% of those treated with lanreotide 30 mg. The respective figures for IGF-I normalization were 66 and 48%. However, a large majority of the patients enrolled in these studies were preselected for SRIF analog responsiveness (8) . Therefore, several studies were initiated in which newly diagnosed patients were treated with somatostatin analogs. To date, efficacy numbers have been reported for normalizing GH (43-79%) and IGF-I (53-68%), which are comparable with efficacy numbers for adjuvant SRIF analog therapy (9) (10) (11) (12) (13) (14) (15) .
Human GH-secreting pituitary adenomas express multiple sst subtypes. sst 2 and sst 5 receptors are the predominantly expressed sst, both at the mRNA (Table 1 ; (16) (17) (18) (19) ) and the protein level (20) . Several studies reported a variable sst 2 mRNA expression and a relatively high expression of sst 5 (16, 18, 21) . The sst 2 seems a predominant receptor in determining the inhibitory effect of OCT or lanreotide on circulating GH release in acromegalic patients. sst 2 mRNA expression in GH-secreting pituitary adenomas shows a positive correlation with the in vivo GH suppression induced by an acute test using a single injection of 200 mg OCT (21) , as well as with the in vitro and in vivo responsiveness to OCT in another series of patients (18) . Moreover, it has recently become clear that apart from sst 2 , sst 5 receptors play an important role in regulating GH secretion by human GH-secreting pituitary adenoma cells as well. In this respect, the regulation of fetal human GH secretion (22) is similar to that in human GH-secreting pituitary adenomas. In primary cultures of human GH-secreting pituitary adenomas, new SRIFanalogs with enhanced sst 2 -binding affinities inhibit GH secretion more potently compared with the clinically used octapeptide SRIF analogs, OCT and lanreotide. In addition, some adenomas show a better response to sst 2 -specific analogs, whereas in others sst 5 -specific analogs are more potent in suppressing GH release (23) . Moreover, the combined activation of sst 2 and sst 5 results in additive inhibitory effects on GH secretion. Interestingly, the sst 5 preferential analog BIM-23 268 inhibited GH release in only 7 of 15 cases, whereas, in agreement with the results of Shimon and coworkers (23) , partial additive effects in suppressing GH release were found in OCT-partially responding cultures when the sst 2 -and sst 5 -specific compounds were used in combination. Taking these data together, it can be concluded that sst 2 is the predominant receptor in regulating GH release by GH-secreting pituitary adenoma cells, whereas sst 5 receptors may mediate an inhibitory effect on GH secretion as well. The additive inhibitory effects on GH release following activation of both sst 2 and sst 5 are probably mediated via a functional association of both sst subtypes. Ren and coworkers (24) demonstrated in human fetal pituitary cell cultures that an sst 2 selective antagonist was capable of reversing the GH suppressive effects of sst 2 /sst 5 biselective agonists or that of sst 2 and sst 5 agonists in combination, suggesting a functional interaction between both sst subtypes. In adenomas co-secreting GH and prolactin (PRL), PRL secretion is preferentially inhibited by sst 5 -specific SRIF analogs (16, 18, 23) . The observed additive GH-suppressive effect of activating both sst 2 and sst 5 also initiated the development of analogs with selectivity to multiple sst subtypes. One of these compounds, the sst 2 -and sst 5 -bispecific compound BIM-23 244, indeed inhibits GH release in a subgroup of partially OCTsensitive adenomas more potently when compared with OCT. In this subgroup of adenomas sst 2 mRNA expression was ninefold lower, and sst 5 mRNA expression approximately sevenfold higher than in the OCT-sensitive adenomas (21) . These studies suggest that in tumors expressing a low sst 2 level and a high sst 5 /sst 2 ratio, sst 5 is of increasing importance in regulating GH release (21) . Another recently developed compound has a more universal sst-binding profile. This compound, named SOM230, has a 25-, 5-and 40 times higher binding affinity to sst 1 , sst 3 , and sst 5 receptors respectively, and 2.5 times lower affinity to sst 2 , when compared with OCT (25) . The SOM-230 inhibits GH release in a higher number of GH-secreting pituitary adenomas, both in vitro (18) and in vivo (see below). SOM230 suppressed GH secretion in primary cultures from human fetal pituitary cells (26) . The preclinical reports of enhanced GH suppression via the combined activation of sst 2 and sst 5 receptors in cultures of GH-secreting pituitary adenomas initiated a proofof-concept clinical trial with SOM230 in 12 patients with active acromegaly (27) . A single s.c. injection of 250 mg SOM230 compared with 100 mg OCT showed comparable efficacy in suppressing circulating GH concentrations in eight patients, and showed a significantly enhanced suppression in 3 of 12 acromegalic patients (27; Fig. 1 ). The observation that SOM230 demonstrates potent inhibitory effects upon GH release in patients with GH-secreting pituitary adenomas expressing a low amount of sst 2 and a high amount of sst 5 suggests that the sst 5 subtype may indeed play an essential role in mediating in vivo GH suppressive actions in OCT-partial responders. Therefore, the enhanced efficacy of SOM230 can be explained by high sst 5 expression in this type of adenomas and its 40-fold higher binding affinity for sst 5 as compared with OCT. Since SOM230 is able to lower GH levels in both OCT responders and partial responders, this novel SRIF analog has a clear advantage over OCT and might increase the number of patients that can be biochemically controlled during long-term medical treatment.
Finally, a role for sst 1 in the control of GH-secreting pituitary adenoma cell function has been proposed. 
ACTH-secreting pituitary adenomas
The endogenous Cushing's syndrome is predominantly caused by excess adrenocorticotropin (ACTH) release from an ACTH-secreting pituitary adenoma, also known as Cushing's disease (CD; (30) 5 receptors seem more resistant to DEX. This was indeed confirmed by the mRNA as well as by the sst membranebinding studies. These data suggest that in untreated patients with CD the expression level of sst 2 is too low for OCT to lower ACTH and cortisol levels. Indeed, relatively low levels of sst 2 mRNA in a series of primary human corticotrope adenomas of patients with CD were found. On the other hand, a predominant expression of sst 5 mRNA in corticotrope adenomas was observed (42) . This sst mRNA profile in human corticotrope adenomas, i.e. a low sst 2 and a significant sst 5 mRNA expression, supports the concept that glucocorticoids down-regulate sst 2 expression in human corticotrope adenomas, while sst 5 receptors are more resistant to glucocorticoid pressure. These observations also support the lack of efficacy of OCT in lowering circulating ACTH and cortisol levels in these patients, because sst 2 expression is too low and sst 5 membrane binding affinity of OCT is not high enough to make OCT therapeutically active in patients with CD. Support is formed by SOM230-induced inhibition of basal and CRH-stimulated ACTH release by the corticotrophe adenomas, which appeared comparable with the observations in AtT20-cells, i.e. significant inhibition by SOM230 when compared with OCT, even in the presence of DEX. SOM230 did not inhibit AtT20 cell-proliferation or pro-opiomelanocortin synthesis during 72 h incubation in vitro. Therefore, increased ACTH breakdown may form an additional explanation for the inhibitory effect of SOM230 (and SRIF) on basal ACTH secretion. It is suggested, therefore, that sst 2 Csst 5 preferring SRIF analogs, such as SOM230, might become of therapeutic interest in CD. The suppression of ACTH levels by activation of sst 5 in patients with CD might lower cortisol levels. Since cortisol lowers sst 2 expression, these suppressive effects might subsequently be (partially) abrogated, and enhanced ACTH inhibition via restored sst 2 expression becomes suggestive. Therefore, prolonged treatment with SOM230 may be able to lower ACTH levels in CD even more, because it could now function via both sst 5 and sst 2 receptor subtypes (Fig. 2 ). An open label phase II trial in nine patients with untreated or recurrent CD has demonstrated promising results with SOM230 (43). After 2 weeks of SOM230 treatment, 600 mg s.c. twice daily, free urinary cortisol levels normalized in three patients, while in the remaining six patients urinary cortisol levels were suppressed by 17-60%. A prolonged treatment shall reveal whether this multiligand can indeed be of clinical potential for this serious neuroendocrine condition. On the other hand, glucose intolerance in all patients studied was documented during this short treatment period, and one patient even withdrew from the trial due to overt diabetes mellitus. In addition, a transient increase in glucose levels after SOM230 was already observed in acromegalic patients (44) , whereby SOM230 was well tolerated and, in contrast to OCT, did not suppress insulin concentrations. Even though patients with CD and acromegaly are already known to suffer from glucose intolerance, it seems crucial for the future clinical development of SOM230 to retrieve answers with respect to this serious side effect.
Prolactinomas
Dopamine agonists have been shown to be highly effective in the medical treatment of PRL secreting pituitary adenomas (45, 46) . Still, several patients seem intolerant for these drugs and some of them are resistant or partially responsive to DA agonist treatment. Therefore, can SRIF analogs become of interest to treat this small group of prolactinoma patients? In three DA agonist sensitive prolactinomas, SOM230 was significantly more potent than OCT in lowering PRL secretion in vitro (18) . In two of the prolactinomas, there was a clear relationship between the expression of sst 5 mRNA in the adenoma cells and the percentage inhibition of PRL secretion by SOM230. In one prolactinoma culture, which expressed high levels of sst 5 mRNA and no other sst mRNAs, PRL secretion was reduced to the same extent as that induced by bromocriptine (Fig. 3) . One other prolactinoma, which showed a significantly lower responsiveness to SOM230, had very low sst 5 mRNA levels. The lower potency of OCT in reducing PRL secretion by prolactinomas seems related to the very low sst 2 levels as demonstrated in a series of 10 prolactinomas by Jaquet et al. (47) . These data further underline the role of sst 5 in mediating its suppressive effect on PRL secretion. However, as already mentioned, the potential clinical importance of these findings should be considered in view of the very high proportion of patients with prolactinomas responding to DA agonist treatment with a normalization of PRL levels and tumor shrinkage (45, 46) . In addition, Jaquet et al. (47) showed previously that the effects of sst 5 selective compounds on prolactinoma cells are superimposable, at higher concentrations to those of the DA agonists, but not additive, particularly in adenomas resistant to dopaminergic suppression of PRL release. The elevated ACTH and cortisol levels down-regulate sst 2 expression on the tumor, making it almost impossible for the current clinically available sst 2 -preferring SRIF-analogs to inhibit ACTH and cortisol secretion (left). SOM230, however, through activation of sst 5 , should be able to lower ACTH and cortisol levels. In this relative hypocortisolemic state, the down-regulation of sst 2 by cortisol might be abrogated. Subsequently, because SOM230 also binds with good affinity to sst 2 , enhanced suppression of ACTH and cortisol via restored sst 2 expression becomes suggestive (right).
TSH-secreting pituitary adenomas
TSH-secreting pituitary adenomas are rare and transsphenoidal surgery is considered the first treatment approach for these tumors, leading to normalization of thyroid hormone levels and the disappearance of pituitary tumors in approximately 44% of patients (48, 49) . The current clinically available SRIF analogs OCT and lanreotide induce normalization of thyroid hormone levels in the large majority of patients with TSH-secreting adenomas, although limited data are available. In approximately 80% of patients normalization of TSH levels has been reported, while significant tumor shrinkage is observed in 50% of cases (49) (50) (51) . These data suggest that sst 2 receptors seem to be involved in the beneficial effects of the current clinically available sst 2 -preferring SRIF analogs. 
Clinically non-functioning pituitary adenomas

Conclusion
In the last two decades, SRIF analogs were used for the treatment of hormone-secreting pituitary adenomas. However, a significant proportion of these patients were found to be (partially) resistant to the suppressive effects of current clinically available sst 2 -preferring SRIF analogs. With the improved understanding of SRIF and sst physiology and interactions, and with the increasing involvement of the industry in novel SRIF formulation production, well-characterized sst selective and universal SRIF analogs were developed. Using these novel SRIF analogs in in vitro pituitary cell cultures resulted in new concepts and potential mechanisms for the treatment of pituitary hormone hypersecretion. These concepts include ligand binding to both sst 2 and sst 5 or to sst 1 alone, resulting in greater efficacy to suppress GH in acromegaly; binding to sst 5 to suppress PRL in prolactinomas; binding to predominantly sst 5 and concomitantly to sst 2 resulting in suppression of ACTH release in CD; and finally, binding to sst 3 might induce pituitary adenoma cell shrinkage in NFAs. In addition, interactions among sst subtypes and receptors of other G-protein coupled receptors, such as the dopamine D2 receptor, may form another therapeutic tool in the medical treatment of pituitary adenomas (54) (55) (56) (57) (58) (59) . This interactive multireceptor system of ligand activation and cross-talk at the membrane and intracellular levels may improve manipulation of pituitary hormone regulation, and enhance efficacy of medical therapy for pituitary hormone hypersecretion. 
